| Literature DB >> 35401834 |
Yong Zhang1, Haonan Yang2,3, Yanbao Yu4, Ying Zhang2,3.
Abstract
Nanostructured devices and nanoparticles have fundamentally reshaped the development of precision healthcare in recent decades. Meanwhile, mass spectrometry (MS)-based proteomics has evolved from simple protein sequencing to a powerful approach that identifies disease patterns and signatures, reveals molecular mechanisms of pathological processes, and develops therapeutic or preventive drugs. Significantly, the two distinct disciplines have synergized and expanded our knowledge about human health and disease, as evidenced by a variety of nanotechnology-assisted sample processing strategies, facilitating in-depth proteome profiling and post-translational modifications (PTMs) characterization. This review summarizes recent advances in nanoparticle design for better enrichment of marker proteins and their PTMs from various bio-specimens and emerging nanotechnologies that are applied to MS-based proteomics for precision medicine discovery. © The author(s).Entities:
Keywords: Nanoparticle; biomarkers; mass spectrometry; nanotechnology; post- translational modifications; proteomics
Mesh:
Substances:
Year: 2022 PMID: 35401834 PMCID: PMC8965478 DOI: 10.7150/thno.64325
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.600
Figure 2Nanotechnologies for enriching phosphopeptides. (A, B) Principle and example of phosphopeptides enrichment by Immobilized metal ion affinity chromatography (IMAC) method. (C, D) Principle and example of phosphopeptides enrichment by metal oxide affinity chromatography (MOAC) method. Adapted with permission from Ref. 27. Copyright 2012 American Chemical Society.]
Summary of the nanotechnologies in PDPM discussed in this review.
| Nanotechnology | Target | Type of technology and material | Application | Main findings | Ref. | |
|---|---|---|---|---|---|---|
| Specific enrichment | Phosphorylated protein | Immobilized metal ion affinity chromatography (IMAC) | Ti4+ -immobilized magnetic composite microspheres | Milk and Human Serum | Efficient separation phosphopeptide/nonphosphopeptide = 1:500) |
|
| Metal oxide affinity chromatography (MOAC) | Titanium dioxide (TiO2) beads | Liver proteins | Nearly 30,000 phosphorylation sites and several hyper-phosphorylation of signaling pathways in HCC |
| ||
| Ti4+-functionalized dendrimer | Plasma Microvesicles and Exosomes | 144 phosphoproteins among the over 10,000 unique phosphopeptides are significantly higher in patients diagnosed with breast cancer compared with healthy controls |
| |||
| Glycosylated protein | Magnetic nanomaterials | Aminooxy-functionalized magnetic nanoparticle | Asialofetuin from fetal calf serum and myoglobin from horse heart | Highly efficient separation of N-glycoproteins with excellent sensitivity and be able to effectively analyze a small sample |
| |
| Boronic acid functionalized nano systems | Dendrimeric boronic acid-functionalized magnetic nanoparticles | Human saliva | Exhibited a strong avidity towards glycoproteins, which was 3-4 orders of magnitude higher than the conventional boronate affinity of a single binding. |
| ||
| SNO-proteome | Fluorous solid-phase extraction | nanographite fluoride | Human Umbilical Vein Endothelial Cell (HUVEC) | Better selectivity, lower limit of detection, and higher post enrichment recovery as well as large enrichment capacity. | ||
| Low abundance protein | Antibody-immobilized magnetic nanomaterial | Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) | Human plasma, human mammary epithelial cell line | Can enrich specific peptides from a mixture, the antibody-coupled beads can be reused consistently for up to 10 times. | ||
| Magnetic nanomaterials | Surface-functionalized superparamagnetic iron-oxide (magnetite, Fe3O4) | Human plasma | Specifically enrich cardiac troponin I (cTnI), a well-established cardiac biomarker |
| ||
| Non-specific enrichment | Protein corona | Magnetic nanomaterials | 43 types of magnetic nanoparticles | Human plasma | 10 of them can achieve efficient plasma proteome profiling across more than seven orders of magnitude, including the identification of 53 FDA-approved protein biomarkers in a single pooled plasma. |
|
| Circulating tumor cells (CTCs) | Non-magnetic nanomaterials | TiO2 nanorods (160-300 nm diameter) on F-doped SnO2 (FTO) substrate | Artificial blood samples | Can effectively enhance the capture performance of target cancer cells even in a low cell density situation. |
| |
| Nanomaterials with different size | Tandem flexible micro spring array (tFMSA) | Human blood | Increasing the CTCs capture efficiency to 90% |
| ||
| Extracellular Vesicles | Magnetic nanomaterials | Bifunctional magnetic beads (BiMBs) | Urine | Higher enrichment efficiency and lower sample consumption |
| |
| Tangential flow filtration (TFF) | nano-membranes | Undiluted Serum | Operating pressures are orders-of-magnitude lower than membranes with conventional thicknesses (1-10 µm). Captured particles are associated with a surface, rather than trapped in a bulk-matrix. Higher efficiency of capture and release of particles. |
| ||
| LCMS analysis | Protein digestion | Magnetic, chromatographic or agarose beads | Functionalized paramagnetic beads | Presented a novel protocol using paramagnetic beads, Single-Pot Solid-Phase-enhanced Sample Preparation (SP3). |
| |
| Electrospray ionization emitters | Nanoflow LC | Microfabricated monolithic multinozzle emitter | Low-volume whole blood samples | Achieved a detection limit of less than 5 red blood cells |
| |
| LC columns | Microfabricated pillar array columns | A 2-um i.d. narrow open tubular column running at picoflow (< 800 pl/min) | Tryptic peptides | Provide nearly 1,000 protein identifications from only less than 100 pg tryptic digests |
| |
| Micro-pillar array column (μPAC) | Tryptic digest of a mixture of seven proteins with diverse mass and isoelectric point | High flow rates (600 nl/min) and higher protein identification rates. |
| |||